

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/673,710	03/07/2001	Sylvia Burssens	2364/100	3986		
	7590 09/25/2002		•			
ANN R. POK DILWORTH &	ALSKY, ESQ. & BARRESE	EXAMINER				
	VINGTON BLVD.		COLLINS, CYNTHIA E			
			ART UNIT	PAPER NUMBER		
			1638	α		
			DATE MAILED: 09/25/2002	7		

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary			Applica	tion N	0.	Applicant(s)			
			09/673,	710		BURSSENS ET AL.			
			Examin			Art Unit			
			Cynthia	Collins	5	1638			
Pariod fo	The MAILING DATE of this commun	nication	appears on th	ne cov	er sheet with th	correspondence add	dress		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any - Status									
1)🖂	Responsive to communication(s) fi	iled on <u>0</u>	9 March 200	<u>1</u> .					
2a)	This action is FINAL .	2b)⊠	This action is	s non-	final.				
3)	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Dispositi	on of Claims								
4)🖂	4)⊠ Claim(s) <u>1-31</u> is/are pending in the application.								
4a) Of the above claim(s) is/are withdrawn from consideration.									
	Claim(s) is/are allowed.								
6) Claim(s) is/are rejected.									
7)	Claim(s) is/are objected to.								
8) Claim(s) 1-31 are subject to restriction and/or election requirement.									
Application	Application Papers								
9) <u></u> ⊤	9)☐ The specification is objected to by the Examiner.								
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.									
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11) 🔲 T	11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action.									
12) The oath or declaration is objected to by the Examiner.									
	nder 35 U.S.C. §§ 119 and 120								
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).									
a)[All b) Some * c) None of:								
1	. Certified copies of the priority of	documer	nts have bee	n rece	eived.				
2	Certified copies of the priority of	documer	nts have bee	n rece	eived in Applicatio	n No			
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 									
	14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.									
Attachment(s			Financy of		2 0.0.0. 33 120 6	411G/OF 12 1.			
2) 🔲 Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PT tion Disclosure Statement(s) (PTO-1449) Pa	O-948) per No(s) ₋	·	5) 📙	Interview Summary (Notice of Informal Pa Other:	PTO-413) Paper No(s). Itent Application (PTO-1	. 52)		

Application/Control Number: 09/673,710

Art Unit: 1638

- ie.

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-14 and 16-31, drawn to a method for obtaining plants tolerant to abiotic stress conditions by introducing into a plant cell a CDK nucleic acid molecule that results in the presence of a CDK protein that is not susceptible to inhibitory phosphorylation.

Group II, claim(s) 1-11, 13 and 15-31, drawn to a method for obtaining plants tolerant to abiotic stress conditions by introducing into a plant cell a Wee-kinase nucleic acid molecule that results in the presence of a CDK protein that is not susceptible to inhibitory phosphorylation.

Group III, claim(s) 1-11, 13 and 15-31, drawn to a method for obtaining plants tolerant to abiotic stress conditions by introducing into a plant cell a MIK nucleic acid molecule that results in the presence of a CDK protein that is not susceptible to inhibitory phosphorylation.

Group IV, claim(s) 1-11, 13 and 15-31, drawn to a method for obtaining plants tolerant to abiotic stress conditions by introducing into a plant cell a MYT nucleic acid molecule

Application/Control Number: 09/673,710

Art Unit: 1638

. .

that results in the presence of a CDK protein that is not susceptible to inhibitory phosphorylation.

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical feature linking the inventions of Groups I-IV appears to be the introduction into a plant cell of a nucleic acid molecule that results in the presence of a CDK protein that is not susceptible to inhibitory phosphorylation. However, the introduction into a plant cell of a nucleic acid molecule that results in the presence of a CDK protein that is not susceptible to inhibitory phosphorylation is obvious or anticipated over Hemerly et al. (The EMBO Journal, Vol. 14, No. 16, pages 3925-3936, 1995, Applicant's Search Report), and therefore does not constitute a special technical feature as defined by PCT Rule 13.2, because it does not define a contribution over the prior art. Furthermore, the methods of Groups I-IV employ structurally and functionally distinct nucleic acids encoding structurally and functionally distinct polypeptides. While CDK, Wee-kinase MIK and MYT share a common activity, namely resulting in the presence of a CDK protein that is not susceptible to inhibitory phosphorylation, this common activity is not a special technical feature, as discussed supra. Additionally, CDK, Wee-kinase MIK and MYT do not share a common structure or significant structural element that is a contribution over the prior art, and thus CDK, Wee-kinase MIK and MYT do not constitute a special technical feature.

Application/Control Number: 09/673,710

Art Unit: 1638

Page 4

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Remarks

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cynthia Collins whose telephone number is (703) 605-1210. The examiner can normally be reached on Monday-Friday 8:45 AM -5:15 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson can be reached on (703) 306-3218. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

CC

September 10, 2002

PHUONG T. BUI

PHIMARY EXAMINER